Research programme: miRNA therapeutics - Synlogic

Drug Profile

Research programme: miRNA therapeutics - Synlogic

Alternative Names: let-7; let-7 mimic; let-7b; let-7c; let-7g; miR-101; miR-192; miR-215; miR-Rx01; miR-Rx02; miR-Rx03; miR-Rx04; miR-Rx05; miR-Rx06; miR-Rx07; miR-Rx16; miR-Rx16 mimic; miR-Rxlet-7; Tumour suppressor microRNAs - Synlogic

Latest Information Update: 29 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asuragen
  • Developer Mirna Therapeutics; Synlogic; University of Texas M. D. Anderson Cancer Center
  • Class MicroRNAs
  • Mechanism of Action Oncogene protein inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bladder cancer; Gastric cancer; Ovarian cancer
  • No development reported Colorectal cancer; Haematological malignancies; Liver cancer; Non-small cell lung cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 28 Aug 2017 Synlogic has merged with Mirna Therapeutics forming Synlogic
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Colorectal-cancer in USA
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Haematological-malignancies in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top